Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1972 Nov;6(5):743–747. doi: 10.1128/iai.6.5.743-747.1972

Hyporeactivity of Infection: Potential Limitation to Therapeutic Use of Interferon-Inducing Agents

D A Stringfellow 1, L A Glasgow 1
PMCID: PMC422604  PMID: 4344367

Abstract

Interferon inducers are generally most effective as antiviral agents when used prophylactically. One possible explanation for this is that animals develop a state of hyporeactivity during the course of a virus infection. Such a progressive loss of capacity to produce interferon was observed with a representative group of interferon-inducing agents (polyinosinic-cytidylic acid, Tilorone hydrochloride, New-castle disease virus, or a strain of encephalomyocarditis virus) during the course of a model picornavirus infection in mice.

Full text

PDF
743

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Buckler C. E., DuBuy H. G., Johnson M. L., Baron S. Kinetics of serum interferon response in mice after single and multiple injections of polyI-poly C. Proc Soc Exp Biol Med. 1971 Feb;136(2):394–398. doi: 10.3181/00379727-136-35272. [DOI] [PubMed] [Google Scholar]
  2. Cate T. R., Kelly J. R. Hong Kong influenza antigen sensitivity and decreased interferon response of peripheral lymphocytes. Antimicrob Agents Chemother (Bethesda) 1970;10:156–160. [PubMed] [Google Scholar]
  3. Colby C., Morgan M. J. Interferon induction and action. Annu Rev Microbiol. 1971;25:333–360. doi: 10.1146/annurev.mi.25.100171.002001. [DOI] [PubMed] [Google Scholar]
  4. De Clercq E., Merigan T. C. Current concepts of interferon and interferon induction. Annu Rev Med. 1970;21:17–46. doi: 10.1146/annurev.me.21.020170.000313. [DOI] [PubMed] [Google Scholar]
  5. Hilleman M. R. Prospects for the use of double-stranded ribonucleic acid (poly I:C) inducers in man. J Infect Dis. 1970 Feb;121(2):196–211. doi: 10.1093/infdis/121.2.196. [DOI] [PubMed] [Google Scholar]
  6. ISAACS A., LINDENMANN J. Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci. 1957 Sep 12;147(927):258–267. doi: 10.1098/rspb.1957.0048. [DOI] [PubMed] [Google Scholar]
  7. Lindh H. F., Lindsay H. L., Mayberry B. R., Forbes M. Polyinosinic-cytidylic acid complex (poly I:C) and viral infections in mice. Proc Soc Exp Biol Med. 1969 Oct;132(1):83–87. doi: 10.3181/00379727-132-34153. [DOI] [PubMed] [Google Scholar]
  8. Murphy B. R., Glasgow L. A. Factors modifying host resistance to viral infection. 3. Effect of whole body x-irradiation on experimental encephalomyocarditis virus infection in mice. J Exp Med. 1968 May 1;127(5):1035–1052. doi: 10.1084/jem.127.5.1035. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Nemes M. M., Tytell A. A., Lampson G. P., Field A. K., Hilleman M. R. Inducers of interferon and host resistance. VI. Antiviral efficacy of poly I:C in animal models. Proc Soc Exp Biol Med. 1969 Nov;132(2):776–783. doi: 10.3181/00379727-132-34308. [DOI] [PubMed] [Google Scholar]
  10. Osborn J. E., Medearis D. N., Jr Studies of relationship between mouse cytomegalovirus and interferon. Proc Soc Exp Biol Med. 1966 Mar;121(3):819–824. doi: 10.3181/00379727-121-30897. [DOI] [PubMed] [Google Scholar]
  11. Osborn J. E., Medearis D. N., Jr Suppression of interferon and antibody and multiplication of Newcastle disease virus in cytomegalovirus infected mice. Proc Soc Exp Biol Med. 1967 Feb;124(2):347–353. doi: 10.3181/00379727-124-31740. [DOI] [PubMed] [Google Scholar]
  12. Park J. H., Baron S. Herpetic keratoconjunctivitis: therapy with synthetic double-stranded RNA. Science. 1968 Nov 15;162(3855):811–813. doi: 10.1126/science.162.3855.811. [DOI] [PubMed] [Google Scholar]
  13. VILCEK J., RADA B. Studies on an interferon from tickborne encephalitis virus-infected cells (IF). III. Antiviral action of IF. Acta Virol. 1962 Jan;6:9–16. [PubMed] [Google Scholar]
  14. Youngner J. S., Stinebring W. R. Interferon appearance stimulated by endotoxin, bacteria, or viruses in mice pre-treated with Escherichia coli endotoxin or infected with Mycobacterium tuberculosis. Nature. 1965 Oct 30;208(5009):456–458. doi: 10.1038/208456a0. [DOI] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES